DEFINING CYTOKINES CONTENTS IN SOLVING MAIN CUNICAL ISSUES

Breakthroughs in cytokine biology, appraisal of their importance in many diseases, and successes of anticytokine therapy have lead to an assumption that cytokines can be used as biomarkers in various clinical settings. The aim of this review is to discuss some data from the literature and our own data pertaining to the use of cytokines as biomarkers for the assessment of disease burden, prognosis, diagnosis, and prediction of response to treatment

AUTOIMMUNE DISEASES AND ATHEROSCLEROSIS - PROBLEMS OF TREATMENT

The problem of comorbidity is one of the most important problems in clinical immunology. The commonest non-organ specific autoimmune diseases — rheumatoid arthritis (RA) and psoriasis are linked with accelerated atherosclerosis progression and increased cardiovascular risk. In autoimmune disorders associated with comorbidities the use of multitargeted drugs holds a promise. Examples of such drugs include the inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins) and agonists of PPARα (fibrates) which exert antiinflammatory, immunomodulating, and anti-atherogenic activities. In this review we summarize our own research on statins and fibrates pre-clinical pharmacology, their efficacy and safety in patients with RA and psoriasis

EFFICACY AND SAFETY OF IMMUNOMODULATORS APPLICATION IN PREVENTION OF COMPLICATIONS IN PATIENTS WITH PERTUSSIS

Pertussis is an urgent pediatric problem due to its frequency and severity in the first year of life. One of the most threatening complications of pertussis is pneumonia. In a parallel, non-randomized open-label study we have demonstrated clinical efficacy and safety of immunomodulators for the prophylaxis of bacterial complications of pertussis